Neopharm to market Prima BioMed's ovarian cancer drug in Israel

Australia-based Prima BioMed (Prima) has granted an exclusive license to Neopharm Group (Neopharm) to market and sell CVac, its personalised immunocellular therapeutic product, in Israel and Palestine.
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news